What is DCL Pathology?
Operating out of Indianapolis, DCL Pathology functions as a specialized private laboratory with a deep-rooted history spanning over three decades. The firm distinguishes itself through a high-level focus on fine needle biopsy services and fine needle aspiration, having successfully diagnosed more than 50,000 cases. Their market position is defined by a unique intersection of clinical trial support and advanced diagnostic pathology, providing essential, integrated services to global sponsors and central laboratories. As a pioneer in minimally-invasive diagnostic procedures, DCL Pathology serves as a vital partner for organizations navigating the complexities of modern drug development and therapeutic validation.
How much funding has DCL Pathology raised?
DCL Pathology has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in DCL Pathology
PPP
Public-Private Partnership
What's next for DCL Pathology?
With the successful completion of this late-stage financing, DCL Pathology is strategically positioned to expand its global footprint and enhance its technological infrastructure. The firm is expected to prioritize the integration of advanced digital pathology tools and the scaling of its diagnostic throughput to meet the increasing demand for high-fidelity clinical trial data. By reinforcing its core competencies in fine needle aspiration and anatomic pathology, the company aims to solidify its status as a preferred partner for large-scale, complex clinical research initiatives. Future growth will likely focus on deepening relationships with international sponsors and optimizing the efficiency of its diagnostic workflows to maintain its competitive edge in the life sciences sector.
See full DCL Pathology company page
